Hypoxia and anaemia in head and neck squamous cell carcinoma - Mechanisms of therapy failure and provision of new therapeutic targets

Clinical Otolaryngology

Volumn 30, Issue 2, 2005, Pages 99-104

  Winter S C A , ^a   Corbridge, R J ^b   Cox, G J ^b   Harris, A L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 METHOXYESTRADIOL; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR ANTAGONIST; IMATINIB; OXYGEN; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SORAFENIB; TIRAPAZAMINE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN ANTAGONIST;

ANEMIA; ANGIOGENESIS; APOPTOSIS; CANCER INCIDENCE; CANCER SURVIVAL; ERYTHROPOIESIS; GLYCOLYSIS; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; OXYGEN BLOOD LEVEL; OXYGEN TISSUE LEVEL; PH MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE;

ANEMIA; ANOXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ENVIRONMENT; ERYTHROPOIESIS; HEAD AND NECK NEOPLASMS; HUMANS; HYDROGEN-ION CONCENTRATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OXYGEN; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TREATMENT FAILURE;

EID: 17644402123     PISSN: 17494478     EISSN: 17494486     Source Type: Journal    
DOI: 10.1111/j.1365-2273.2004.00946.x     Document Type: Review

References (25)

1. Harris A.L. (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2, 38-47
2. Harrison L.B., Chadha M., Hill R.J. et al. (2002) Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7, 492-508
3. Kumar P. (2000) Impact of anemia in patients with head and neck cancer. Oncologist 5 (Suppl. 2), 13-18
4. Harrison L.B., Shasha D. & Homel P. (2002) Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology 63 (Suppl. 2), 11-18
5. Becker A., Stadler P., Lavey R.S. et al. (2000) Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 46, 459-466
6. Nordsmark M., Loncaster J., Aquino-Parsons C. et al. (2003) Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother. Oncol. 67, 35-44
7. Loncaster J.A., Harris A.L., Davidson S.E. et al. (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 61, 6394-6399
8. Nordsmark M. & Overgaard J. (2000) A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother. Oncol. 57, 39-43
9. Rudat V., Vanselow B., Wollensack P. et al. (2000) Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiother. Oncol. 57, 31-37
10. Beasley N.J., Leek R., Alam M. et al. (2002) Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 62, 2493-2497
11. Maxwell P.H., Pugh C.W. & Ratcliffe P.J. (2001) Activation of the HIF pathway in cancer. Curr. Opin. Genet. Dev. 11, 293-299
12. Pugh C.W. & Ratcliffe P.J. (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9, 677-684
13. Maxwell P.H., Dachs G.U., Gleadle J.M. et al. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA 94, 8104-8109
14. Brizel D.M., Schroeder T., Scher R.L. et al. (2001) Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 51, 349-353
15. Koukourakis M.I., Giatromanolaki A., Sivridis E. et al. (2001) Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin. Cancer. Res. 7, 3399-3403
16. Wouters B.G., Weppler S.A., Koritzinsky M. et al. (2002) Hypoxia as a target for combined modality treatments. Eur. J. Cancer. 38, 240-257
17. Acs G., Acs P., Beckwith S.M. et al. (2001) Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 61, 3561-3565
18. Silva M., Benito A., Sanz C. et al. (1999) Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J. Biol. Chem. 274, 22165-22169
19. Burri P., Djonov V., Aebersold D.M. et al. (2003) Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 56, 494-501
20. Kurokawa T., Miyamoto M., Kato K. et al. (2003) Overexpression of hypoxia-inducible-factor 1alpha (HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br. J. Cancer. 89, 1042-1047
21. Sowter H.M., Raval R., Moore J. et al. (2003) Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 63, 6130-6134
22. Semenza G.L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 3, 721-732
23. Spirtos N.M., Westby C.M., Averette H.E. et al. (2002) Blood transfusion and the risk of recurrence in squamous cell carcinoma of the cervix: a gynecologic oncology group study. Am. J. Clin. Oncol. 25, 398-403
24. Littlewood T.J., Bajetta E., Nortier J.W. et al. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19, 2865-2874
25. Henke M., Laszig R., Rube C. et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362, 1255-1260